TRITON BIOSCIENCES BETASERON PHASE III STUDY FOR MULTIPLE SCLEROSIS
TRITON BIOSCIENCES BETASERON PHASE III STUDY FOR MULTIPLE SCLEROSIS is targeting a total enrollment of 30 remitting-relapsing multiple sclerosis (MS) patients at 10 centers in the U.S. and Canada. The company, which began treating patients with early stage MS in July, expects the study to last two years, with a Product License Application filing for early 1991. The remitting-relapsing phase of MS occurs during the first 10 years following diagnosis of the disease. The second and final stage of MS is the chronic progressive phase. With Betaseron, Triton will attempt with its beta interferon product to lessen the frequency of "exacerbations" in subjects, and attempt to slow the progression of the disease. Other measures of efficacy will include changes in the duration, severity or consequences of exacerbations that do occur. The MS patient population is estimated at 250,000 in the U.S. and 50,000 in Canada. The randomized, double-blind study will have three treatment groups: one-third will receive placebo, with the remaining patients receiving Beta-seron 9 mil. or 45 mil. units. Patients will self-administer the treatment via subcutaneous injection every other day for two years. Betaseron (beta interferon) was originally developed by Triton parent Shell Oil and Cetus as an anticancer agent. In a consolidation of its biotechnology research activities, Shell formed Triton in 1983 to test the product's therapeutic possibilities and conduct clinical studies. Betaseron "has the ability to modulate the body's immune response in a manner which may be or benefit to patients with MS, a disease which has many damaging autoimmune components," the company said. Triton is also studying Betaseron in AIDS. The firm announced in June that it would be advancing AIDS trials to Phase III in 300 patients treated in 15 centers nationwide ("The Pink Sheet" June 20, T&G-3). Betaseron is being studied in combination with reduced doses of AZT. Triton's pharmaceutical development program also includes another potential AIDS drug, CS-87, which is reported to be nearing the clinical testing phase.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
Sign in to continue reading.
Need a specific report?
1000+ reports available
New to Pink Sheet?
Start a free trial today!
Register for our free email digests: